USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| May 18, 2022 (est) | Mar 31, 2022 | - | $-0.95 | $-0.60 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| May 18, 2022 (est) | Mar 31, 2022 | - | $31.18M | $0.00 |
Calliditas Therapeutics Ab (Publ)'s next estimated earnings date (based on same quarter last year's date) is May 18, 2022 for the fiscal quarter ending Mar 31, 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 1 | $-0.07 | $-0.07 | $-0.07 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $-1.95 | $-2.42 | $-1.55 |
| Dec 2023 | 1 | $3.85 | $3.85 | $3.85 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 0 / 0 | $-0.07 | $-0.39 | $-0.40 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 1 / 0 | $-2.17 | $-1.68 | $-1.18 |
| Dec 2023 | 1 / 0 | $2.32 | $2.11 | $1.53 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 2 | $23.09M | $11.76M | $34.43M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $69.06M | $60.04M | $78.09M |
| Dec 2023 | 2 | $291.69M | $218.73M | $364.65M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 24, 2022 | Dec 2021 | $-0.66 | $-0.95 | -43.94% |
| Nov 18, 2021 | Sep 2021 | $-0.57 | $0.02 | 104.13% |
| Aug 19, 2021 | Jun 2021 | $-0.48 | $-0.73 | -51.11% |
| May 18, 2021 | Mar 2021 | $-0.45 | $-0.60 | -35.21% |
| Feb 18, 2021 | Dec 2020 | $-0.45 | $-0.41 | 9.11% |
| Nov 12, 2020 | Sep 2020 | $-0.26 | $-0.32 | -23.12% |
| Aug 13, 2020 | Jun 2020 | $-0.30 | $-0.17 | 42.37% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 24, 2022 | Dec 2021 | $-1.56 | $-2.26 | - |
| Feb 18, 2021 | Dec 2020 | $-1.25 | $-0.90 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 24, 2022 | Dec 2021 | $0.00 | $31.18M | - |
| Nov 18, 2021 | Sep 2021 | $0.00 | - | - |
| Aug 19, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 18, 2021 | Mar 2021 | $10.00K | $0.00 | - |
| Feb 18, 2021 | Dec 2020 | $0.00 | $400.00K | - |
| Nov 12, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 13, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 24, 2022 | Dec 2021 | $22.77M | $229.35M | 907.23% |
| Feb 18, 2021 | Dec 2020 | $50.00K | $874.00K | 1648.00% |
CALT's next estimated earnings date (based on same quarter last year's report date) is May 18, 2022 for the fiscal quarter ending Mar 31, 2022.
Calliditas Therapeutics Ab (Publ)'s previous earnings date was Feb 24, 2022 for its fiscal quarter ended Dec 31, 2021.
CALT's earnings per share (EPS) was $-0.95, missing the consensus analysts forecast of $-0.66 by -43.94%.
The EPS was lower than the previous fiscal quarter (Sep 2021) by -4108.44%, and lower than the same period a year before (Dec 2020) by 132.27%.
Revenues were $31.18M.
The company reported a net income of $-219.17M.
Free cash flow for the quarter was $-161.25M for the quarter.
CALT ended the quarter with $213.22M in total debt.
Calliditas Therapeutics Ab (Publ)'s previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.
CALT's earnings per share (EPS) was $-2.26, missing the consensus analysts forecast of $-1.56 by 44.60% , and lower than the previous year's EPS (Dec 2020) by 150.08%.
Revenues were $229.35M, better than the forecast of $22.77M by 907.23%, and up by 26141.08% from previous year's revenue.
The company reported a net income of $-500.29M.
Calliditas Therapeutics Ab (Publ) reported a free cash flow of $-461.59M for its fiscal year, compared to $-309.18M a year ago.
The company ended the fiscal year with $213.22M in total debt. lala
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
